Sanford J. Madigan

Dr. Madigan has over 16 years of industry experience and has been instrumental in developing companies' infrastructure, establishing strategic direction, licensing founding and value-added technologies, negotiating strategic partnerships and corporate acquisitions.

Dr. Madigan most recently served as a co-founder and Chief Executive Officer of Strategic Enzyme Applications (SEA), a San Diego-based clean technology company that was established, in part, as a strategic relationship with Monsanto. Prior to founding SEA, Dr. Madigan served in various venture-backed biotechnology companies; participating as a founder and/or senior manager in BioVerdant, Nereus Pharmaceuticals, Ambit, Xenopharm (acquired by Deltagen), X-Ceptor (acquired by Exelixis) and SIBIA Neurosciences (acquired by Merck).

Dr. Madigan received his B.S. in Biochemistry and a Ph.D. in Genetics from The State University of New York at Stony Brook where, as a graduate student, he was awarded the Abrahams Memorial Award for outstanding potential for basic research. He performed his post-doctoral training at The Salk Institute for Biological Studies in La Jolla, California.